Neither ADU-S100 or Poly I:C, lacking any distracting viral immunogens and both clinically relevant antiviral immune adjuvants triggering the STING/cGAS and TLR3 signaling cascade, respectively, were unable to prime OT-I responses at low-doses despite improved CD8 T cell infiltration into the tumor. Here, TLR3 is linked to neoplasm.